Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T L Holyoake

Showing results (21-30 of 65) with videos related to

Pageof 7
Sort By:
Clinical and Laboratory Haematology|July 29, 2004
Fatal peripheral neuropathy following FLA chemotherapyW L Osborne, T L Holyoake, I G McQuaker, et al.
Cytotherapy|June 5, 2002
Cell separation improves the sensitivity of detecting rare human normal and leukemic hematopoietic cells in vivo in NOD/SCID miceT L Holyoake, C Horrocks, T Thomas, et al.
Leukemia|March 21, 2003
Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clonesY L Chee, M A Vickers, D Stevenson, et al.
Cytotherapy|May 15, 2002
The storage and re-infusion of autologous blood and BM as back-up following failed primary hematopoietic stem-cell transplantation: a survey of European practiceB Pottinger, M Walker, M Campbell, et al.
Leukemia|April 18, 2002
Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemiaT L Holyoake, X Jiang, M W Drummond, et al.
British Journal of Haematology|April 1, 1992
Accelerated recovery from drug-induced agranulocytosis following G-CSF therapyW N Patton, T L Holyoake, J M Yates, et al.
Leukemia|April 13, 2011
The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cellsF Pellicano, P Simara, A Sinclair, et al.
British Journal of Haematology|March 5, 2003
A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec)A Drummond, P Micallef-Eynaud, W S Douglas, et al.
Leukemia|February 15, 2008
Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitorsH Konig, M Holtz, H Modi, et al.
Journal of Clinical Pathology|September 1, 1993
Use of plasma ferritin concentration to diagnose iron deficiency in elderly patientsT L Holyoake, D J Stott, P J McKay, et al.
Pageof 7

Showing results (21-30 of 65) with videos related to

Sort By:
Pageof 7
Clinical and Laboratory Haematology|July 29, 2004
Fatal peripheral neuropathy following FLA chemotherapyW L Osborne, T L Holyoake, I G McQuaker, et al.
Cytotherapy|June 5, 2002
Cell separation improves the sensitivity of detecting rare human normal and leukemic hematopoietic cells in vivo in NOD/SCID miceT L Holyoake, C Horrocks, T Thomas, et al.
Leukemia|March 21, 2003
Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clonesY L Chee, M A Vickers, D Stevenson, et al.
Cytotherapy|May 15, 2002
The storage and re-infusion of autologous blood and BM as back-up following failed primary hematopoietic stem-cell transplantation: a survey of European practiceB Pottinger, M Walker, M Campbell, et al.
Leukemia|April 18, 2002
Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemiaT L Holyoake, X Jiang, M W Drummond, et al.
British Journal of Haematology|April 1, 1992
Accelerated recovery from drug-induced agranulocytosis following G-CSF therapyW N Patton, T L Holyoake, J M Yates, et al.
Leukemia|April 13, 2011
The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cellsF Pellicano, P Simara, A Sinclair, et al.
British Journal of Haematology|March 5, 2003
A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec)A Drummond, P Micallef-Eynaud, W S Douglas, et al.
Leukemia|February 15, 2008
Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitorsH Konig, M Holtz, H Modi, et al.
Journal of Clinical Pathology|September 1, 1993
Use of plasma ferritin concentration to diagnose iron deficiency in elderly patientsT L Holyoake, D J Stott, P J McKay, et al.
Pageof 7